Published in Hypertension on May 21, 2007
The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens (2010) 2.23
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension (2008) 1.72
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension (2008) 1.45
Potential markers of preeclampsia--a review. Reprod Biol Endocrinol (2009) 1.44
Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One (2010) 1.25
The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol (2010) 1.23
Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med (2008) 1.20
Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (2013) 1.11
Is inflammation the cause of pre-eclampsia? Biochem Soc Trans (2011) 1.09
Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia. Hypertension (2007) 1.09
Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency. Ther Adv Neurol Disord (2010) 1.08
Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med (2011) 1.07
The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG (2010) 1.01
Upregulation of long noncoding RNA SPRY4-IT1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR-8SV/neo. PLoS One (2013) 0.97
Autonomic circulatory control during pregnancy in humans. Semin Reprod Med (2009) 0.97
Induction of heme oxygenase-1 attenuates sFlt-1-induced hypertension in pregnant rats. Am J Physiol Regul Integr Comp Physiol (2011) 0.96
An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med (2010) 0.95
Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Rev Cardiovasc Ther (2008) 0.94
Circulating soluble endoglin and placental abruption. Prenat Diagn (2008) 0.93
Gestation dependant changes in angiogenic factors and their associations with fetal growth measures in normotensive pregnancy. PLoS One (2013) 0.92
Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One (2008) 0.89
Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol (2010) 0.89
Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol (2010) 0.88
Relationships between TGFbeta proteins and oxygen concentrations inside the first trimester human gestational sac. PLoS One (2008) 0.88
A comparison of podocyturia, albuminuria and nephrinuria in predicting the development of preeclampsia: a prospective study. PLoS One (2014) 0.86
Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med (2015) 0.85
Variation in endoglin pathway genes is associated with preeclampsia: a case-control candidate gene association study. BMC Pregnancy Childbirth (2013) 0.85
Altered matrix metalloproteinase-2 and -9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy. Biochem Pharmacol (2014) 0.83
Maternal circulating angiogenic factors in twin and singleton pregnancies. Am J Obstet Gynecol (2014) 0.83
Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. J Matern Fetal Neonatal Med (2010) 0.83
Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reprod Biol Endocrinol (2011) 0.83
An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia. Obstet Gynecol Int (2013) 0.83
Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes Control (2011) 0.81
Do anti-angiogenic or angiogenic factors contribute to the protection of birth weight at high altitude afforded by Andean ancestry? Reprod Sci (2010) 0.81
Early detection of maternal risk for preeclampsia. ISRN Obstet Gynecol (2012) 0.81
Maternal angiogenic profile in pregnancies that remain normotensive. Eur J Obstet Gynecol Reprod Biol (2011) 0.79
MiR-101 regulates apoptosis of trophoblast HTR-8/SVneo cells by targeting endoplasmic reticulum (ER) protein 44 during preeclampsia. J Hum Hypertens (2014) 0.79
Second trimester anti-angiogenic proteins and preeclampsia. Pregnancy Hypertens (2012) 0.78
Angiogenic factors in women ten years after severe very early onset preeclampsia. PLoS One (2012) 0.77
Preeclampsia, gestational hypertension and subsequent hypothyroidism. Pregnancy Hypertens (2012) 0.77
Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. Cancer Causes Control (2012) 0.76
First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia. BMC Pregnancy Childbirth (2013) 0.76
Decorin-Mediated Inhibition of Human Trophoblast Cells Proliferation, Migration, and Invasion and Promotion of Apoptosis In Vitro. Biomed Res Int (2015) 0.75
Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia. J Perinatol (2015) 0.75
Expression levels of seven candidate genes in human peripheral blood mononuclear cells and their association with preeclampsia. Hypertens Pregnancy (2013) 0.75
Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational study. Obstet Gynecol Sci (2017) 0.75
Relationships among maternal nutrient intake and placental biomarkers during the 1st trimester in low-income women. Arch Gynecol Obstet (2012) 0.75
A Comparison of 2-Methoxyestradiol Value in Women with Severe Preeclampsia Versus Normotensive Pregnancy. J Clin Diagn Res (2017) 0.75
Response to Plasmapheresis Measured by Angiogenic Factors in a Woman with Antiphospholipid Syndrome in Pregnancy. Case Rep Obstet Gynecol (2015) 0.75
Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med (2011) 0.75
Longitudinal reference ranges for maternal plasma laeverin, and its role as a potential biomarker of preeclampsia. BMC Pregnancy Childbirth (2016) 0.75
A cohort evaluation on arterial stiffness and hypertensive disorders in pregnancy. BMC Pregnancy Childbirth (2012) 0.75
Circulating Levels of sFlt1 Splice Variants as Predictive Markers for the Development of Preeclampsia. Int J Mol Sci (2015) 0.75
Increased Vascular and Uteroplacental Matrix Metalloproteinase-1 and -7 Levels and Collagen I Deposition in Hypertension-in-Pregnancy. Role of TNF. Am J Physiol Heart Circ Physiol (2017) 0.75
Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia. Prog Mol Biol Transl Sci (2017) 0.75
Maternal plasma soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study. J Matern Fetal Neonatal Med (2017) 0.75
Decreased Homodimerization and Increased TIMP-1 Complexation of Uteroplacental and Uterine Arterial Matrix Metalloproteinase-9 during Hypertension-in-Pregnancy. Biochem Pharmacol (2017) 0.75
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int (2002) 8.03
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol (2008) 3.82
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics (2010) 3.39
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis (2009) 2.34
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol (2005) 2.04
Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol (2004) 2.03
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol (2009) 1.95
Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol (2003) 1.91
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation (2009) 1.85
Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Kidney Int (2010) 1.83
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol (2007) 1.80
First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab (2002) 1.79
Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes. Nicotine Tob Res (2007) 1.78
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res (2005) 1.78
Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis (2012) 1.72
Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. J Hypertens (2004) 1.71
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol (2005) 1.71
Postpartum diabetes screening in women with a history of gestational diabetes. Obstet Gynecol (2005) 1.70
Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol (2011) 1.70
Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol (2007) 1.69
Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract (2007) 1.67
Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol (2007) 1.67
Metabolite profiling identifies markers of uremia. J Am Soc Nephrol (2010) 1.63
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ (2009) 1.59
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension (2007) 1.56
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med (2008) 1.54